Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) Other Operating Expenses (2020 - 2025)

Historic Other Operating Expenses for Capricor Therapeutics (CAPR) over the last 10 years, with Q3 2025 value amounting to -$6846.0.

  • Capricor Therapeutics' Other Operating Expenses rose 9939.96% to -$6846.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$38261.0, marking a year-over-year increase of 9664.65%. This contributed to the annual value of -$112805.0 for FY2024, which is 176732.33% down from last year.
  • As of Q3 2025, Capricor Therapeutics' Other Operating Expenses stood at -$6846.0, which was up 9939.96% from -$31415.0 recorded in Q4 2024.
  • Capricor Therapeutics' Other Operating Expenses' 5-year high stood at -$653.0 during Q4 2023, with a 5-year trough of -$1.1 million in Q3 2024.
  • Over the past 5 years, Capricor Therapeutics' median Other Operating Expenses value was -$17900.5 (recorded in 2021), while the average stood at -$129267.8.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first plummeted by 2106315.89% in 2024, then skyrocketed by 9939.96% in 2025.
  • Capricor Therapeutics' Other Operating Expenses (Quarter) stood at -$28955.0 in 2021, then dropped by 18.34% to -$34266.0 in 2022, then soared by 98.09% to -$653.0 in 2023, then crashed by 4710.87% to -$31415.0 in 2024, then soared by 78.21% to -$6846.0 in 2025.
  • Its Other Operating Expenses was -$6846.0 in Q3 2025, compared to -$31415.0 in Q4 2024 and -$1.1 million in Q3 2024.